Cargando…
Checkpoint inhibitor/interleukin‐based combination therapy of cancer
BACKGROUND: Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the recent studies showed that such therapeutic modality suffers from low durability and low or no efficacy for patients with some tumor types...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359865/ https://www.ncbi.nlm.nih.gov/pubmed/35301813 http://dx.doi.org/10.1002/cam4.4659 |